T2	control 565 575	no therapy
T3	eligibility 587 704	patients with HER-2-negative metastatic breast cancer who achieved an objective response to taxane-based chemotherapy
T5	iv-bin-abs 834 836	10
T6	intervention-participants 840 842	36
T7	iv-bin-percent 853 856	28%
T8	cv-bin-abs 871 872	4
T9	control-participants 876 878	19
T10	cv-bin-percent 889 892	21%
T11	outcome 908 918	median PFS
T12	iv-cont-median 923 926	2.8
T13	cv-cont-median 931 941	3.1 months
T14	outcome 1254 1276	Grades III-IV toxicity
T15	iv-bin-percent 1289 1292	69%
T16	outcome 1315 1322	fatigue
T17	iv-bin-percent 1323 1326	31%
T18	outcome 1328 1348	musculoskeletal pain
T19	iv-bin-percent 1349 1352	11%
T20	outcome 1354 1382	neutropenia and thrombopenia
T21	outcome 1383 1385	8%
T22	cv-bin-percent 1391 1394	11%
T23	intervention 49 86	antiangiogenic therapy with sunitinib
T1	outcome 1113 1136	required dose reduction
T4	outcome 771 817	progression-free survival (PFS) > or =5 months
T27	outcome 1211 1226	dose reductions
